Neovasc out of Richmond, British Columbia received the European CE Mark of approval for the Reducer stent for treatment of refractory angina. Unlike traditional stents that are designed to keep a vascular lumen open for efficient blood flow, the Reducer, as the name implies, reduces the cross section of the coronary sinus vein and thereby retrogradely increases the perfusion by oxygenated blood within the myocardium.
The device is implanted in the cath lab in a traditional minimally invasive procedure as any other stent.
Press release: Neovasc Inc. Receives CE Mark for Reducer(TM) Product to Treat Refractory Angina
Product page: Neovasc Reducer…
Flashback: Neovasc Coronary Sinus Reducer: A Novel Stent for Ischemic Heart Disease